Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra

Experimental Neurology

Volumn 166, Issue 1, 2000, Pages 127-135

  Howells, D W ^a   Porritt, M J ^a   Wong, J Y F ^a   Batchelor, P E ^a   Kalnins, R ^a   Hughes, A J ^a   Donnan, G A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Brain derived neurotrophic factor; Dopaminergic; In situ hybridization; Parkinson's disease

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA;

APOPTOSIS; ARTICLE; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; NERVE DEGENERATION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 0033762265     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2000.7483     Document Type: Article

References (45)

1. Neurotrophin trafficking by anterograde transport
2. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease
3. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor
4. trkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: An in situ hybridization study
5. Brain dopamine and the syndromes of Parkinson and Huntington: Clinical, morphological and neurochemical correlations
6. Adrenal medulla grafts enhance recovery of striatal dopaminergic fibres
7. Adrenal medullary autografts into the basal ganglia of Cebus monkeys: Injury-induced regeneration
8. Brain-derived neurotrophic factor and neurotrophin-3 mRNAs are expressed in ventral midbrain regions containing dopaminergic neurons
9. Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration
10. Functional recovery in parkinsonian monkeys treated with GDNF
11. Neuropathology in movement disorders
12. Does adrenal graft enhance recovery of dopaminergic neurons in Parkinson's disease?
13. Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium
14. Surgical damage stimulates proliferation of dopamine uptake sites in normal mouse brain
15. Dopaminergic responses to striatal damage
16. Does reduced BDNF expression contribute to development of Parkinson's disease?
17. What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study
18. Glial cell line-derived neurotrophic factor (GDNF) gene expression in the human brain: A post mortem in situ hybridisation study with special reference to Parkinson's disease
19. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra
20. Molecular cloning of a human gene that is a member of the nerve growth factor family
21. Tissue pH as an indicator of mRNA preservation in human post-mortem brain
22. Putative chromaffin cell survival and enhanced host-derived TH-fiber innervation following a functional adrenal medulla autograft for Parkinson's disease
23. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease
24. Expression of glial cell line-derived neurotrophic factor (GDNF) mRNA following mechanical injury to mouse striatum
25. Axonal regrowth up-regulates beta-actin and Jun D mRNA expression
26. Rate of cell death in parkinsonism indicates active neuropathological process
27. Molecular cloning of rat trkC and distribution of cells expressing messenger RNAs for members of the trk family in the rat central nervous system
28. Beta-Actin is confined to structures having high capacity of remodelling in developing and adult rat cerebellum
29. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease
30. Potential of neurotrophic factors in therapy of Parkinson's disease
31. Dopaminergic stimulation up-regulates the in vivo expression of brain-derived neurotrophic factor (BDNF) in the striatum
32. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra
33. Long-term evaluation of hemiparkinsonian monkeys after adrenal autografting or cavitation alone
34. Sham transplantation protects against 6-hydroxydopamine-induced dopaminergic toxicity in rats: Behavioral and morphological evidence
35. Expression of members of the trk family in the developing postnatal rat brain
36. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase isoforms during neuronal apoptosis
37. Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs
38. BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine
39. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: Involvement of the glutathione system
40. Effects of brain-derived neurotrophic factor on neuronal structure of dopaminergic neurons in dissociated cultures of human fetal mesencephalon
41. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys
42. Research diagnostic criteria for Parkinson's disease
43. Expression of brain-derived neurotrophic factor and TrkB neurotrophin receptors after striatal injury in the mouse
44. BDNF enhances the functional reinnervation of the striatum by grafted fetal dopamine neurons
45. Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia